Moving HIV pre-exposure prophylaxis into clinical settings: Lessons from buprenorphine

American Journal of Preventive Medicine

Volumn 44, Issue 1 SUPPL. 2, 2013, Pages

  Edelman, E Jennifer ^a,b   Fiellin, David A ^a,b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b YALE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUPRENORPHINE; METHADONE;

ARTICLE; DRUG SAFETY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; OPIATE ADDICTION; PATIENT COUNSELING; VIRUS TRANSMISSION;

EID: 84871747258     PISSN: 07493797     EISSN: 18732607     Source Type: Journal    
DOI: 10.1016/j.amepre.2012.09.035     Document Type: Review

References (64)

1. J. Prejean, R. Song, A. Hernandez HIV Incidence Surveillance Group Estimated HIV incidence in the U.S., 2006-2009 PLoS One 6 8 2011 e17502
2. S.A. Strathdee, J.K. Stockman Epidemiology of HIV among injecting and non-injecting drug users: current trends and implications for interventions Curr HIV/AIDS Rep 7 2 2010 99 106
3. S.A. Strathdee, S.G. Sherman The role of sexual transmission of HIV infection among injection and non-injection drug users J Urban Health 80 4S3 2003 iii7 iii14
4. B.D. Marshall, E. Wood Toward a comprehensive approach to HIV prevention for people who use drugs J Acquir Immune Defic Syndr 55 S1 2010 S23 S26
5. L.E. Sullivan, D.A. Fiellin Buprenorphine: its role in preventing HIV transmission and improving the care of HIV-infected patients with opioid dependence Clin Infect Dis 41 6 2005 891 896
6. Anonymous Buprenorphine treatment for opioid dependence CESAR FAX 20 22 2011 Contract No.: 34
7. P. Greene Outpatient drug utilization trends for buprenorphine, years 2002-2009 [power point] 2010
8. J.E. Egan, P. Casadonte, T. Gartenmann The Physician Clinical Support System-Buprenorphine (PCSS-B): a novel project to expand/improve buprenorphine treatment J Gen Intern Med 25 9 2010 936 941
9. Center for Substance Abuse Treatment Clinical guidelines for the use of buprenorphine in the treatment of opioid addiction: a treatment improvement protocol (TIP) series 40 2004 Substance Abuse and Mental Healt Services Administration, DHHS Rockville MD
10. D.A. Fiellin, B.A. Moore, L.E. Sullivan Long-term treatment with buprenorphine/naloxone in primary care: results at 2-5 years Am J Addict 17 2 2008 116 120
11. J. Kakko, K.D. Svanborg, M.J. Kreek, M. Heilig 1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: a randomised, placebo-controlled trial Lancet 361 9358 2003 662 668
12. G.E. Woody, S.A. Poole, G. Subramaniam Extended vs short-term buprenorphine-naloxone for treatment of opioid-addicted youth: a randomized trial JAMA 300 17 2008 2003 2011
13. R.D. Weiss, J.S. Potter, D.A. Fiellin Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: a 2-phase randomized controlled trial Arch Gen Psychiatry 68 12 2011 1238 1246
14. G.M. Myers, K.H. Mayer Oral preexposure anti-HIV prophylaxis for high-risk U.S. populations: current considerations in light of new findings AIDS Patient Care STDs 25 2 2011 63 71
15. T. Kelesidis, R.J. Landovitz Preexposure prophylaxis for HIV prevention Curr HIV/AIDS Rep 8 2 2011 94 103
16. R.M. Grant, J.R. Lama, P.L. Anderson Preexposure chemoprophylaxis for HIV prevention in men who have sex with men N Engl J Med 363 27 2010 2587 2599
17. M.C. Thigpen, P.M. Kebaabetswe, L.A. Paxton Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana N Engl J Med 367 5 2012 423 434
18. J.M. Baeten, D. Donnell, P. Ndase Antiretroviral prophylaxis for HIV prevention in heterosexual men and women N Engl J Med 367 5 2012 399 410
19. A.D. Paltiel, K.A. Freedberg, C.A. Scott HIV preexposure prophylaxis in the U.S.: impact on lifetime infection risk, clinical outcomes, and cost-effectiveness Clin Infect Dis 48 6 2009 806 815
20. K. Desai, S.L. Sansom, M.L. Ackers Modeling the impact of HIV chemoprophylaxis strategies among men who have sex with men in the U.S.: HIV infections prevented and cost-effectiveness AIDS 22 14 2008 1829 1839
21. V. Supervie, J.G. Garcia-Lerma, W. Heneine, S. Blower HIV, transmitted drug resistance, and the paradox of preexposure prophylaxis Proc Natl Acad Sci U S A 107 27 2010 12381 12386
22. M. Martin, S. Vanichseni, P. Suntharasamai Enrollment characteristics and risk behaviors of injection drug users participating in the Bangkok Tenofovir Study, Thailand PLoS One 6 9 2011 e25127
23. K. Underhill, D. Operario, M. Skeer, M. Mimiaga, K. Mayer Packaging PrEP to prevent HIV: an integrated framework to plan for pre-exposure prophylaxis implementation in clinical practice J Acquir Immune Defic Syndr 55 1 2010 8 13
24. L. Weiss, J.E. Egan, M. Botsko, J. Netherland, D.A. Fiellin, R. Finkelstein The BHIVES collaborative: organization and evaluation of a multisite demonstration of integrated buprenorphine/naloxone and HIV treatment J Acquir Immune Defic Syndr 56 S1 2011 S7 S13
25. C.T. Yuan, I.M. Nembhard, A.F. Stern, J.E. Brush Jr, H.M. Krumholz, E.H. Bradley Blueprint for the dissemination of evidence-based practices in health care Issue Brief (Commonw Fund) 86 2010 1 16
26. P.J. Fudala, T.P. Bridge, S. Herbert Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone N Engl J Med 349 10 2003 949 958
27. R.E. Johnson, T. Eissenberg, M.L. Stitzer, E.C. Strain, I.A. Liebson, G.E. Bigelow A placebo controlled clinical trial of buprenorphine as a treatment for opioid dependence Drug Alcohol Depend 40 1 1995 17 25
28. T.R. Kosten, R. Schottenfeld, D. Ziedonis, J. Falcioni Buprenorphine versus methadone maintenance for opioid dependence J Nerv Ment Dis 181 6 1993 358 364
29. W. Ling, D.R. Wesson, C. Charuvastra, C.J. Klett A controlled trial comparing buprenorphine and methadone maintenance in opioid dependence Arch Gen Psychiatry 53 5 1996 401 407
30. C.O. Cunningham, H.V. Kunins, R.J. Roose, R.T. Elam, N.L. Sohler Barriers to obtaining waivers to prescribe buprenorphine for opioid addiction treatment among HIV physicians J Gen Intern Med 22 9 2007 1325 1329
31. C.O. Cunningham, N.L. Sohler, K. McCoy, H.V. Kunins Attending physicians' and residents' attitudes and beliefs about prescribing buprenorphine at an urban teaching hospital Fam Med 38 5 2006 336 340
32. L. Weiss, J. Netherland, J.E. Egan Integration of buprenorphine/naloxone treatment into HIV clinical care: lessons from the BHIVES collaborative J Acquir Immune Defic Syndr 56 S1 2011 S68 S75
33. J. Netherland, M. Botsko, J.E. Egan Factors affecting willingness to provide buprenorphine treatment J Subst Abuse Treat 36 3 2009 244 251
34. D.T. Barry, K.S. Irwin, E.S. Jones Integrating buprenorphine treatment into office-based practice: a qualitative study J Gen Intern Med 24 2 2009 218 225
35. P. Vergara-Rodriguez, M.J. Tozzi, M. Botsko Hepatic safety and lack of antiretroviral interactions with buprenorphine/naloxone in HIV-infected opioid-dependent patients J Acquir Immune Defic Syndr 56 S1 2011 S62 S67
36. L.E. Sullivan, J. Tetrault, D. Bangalore, D.A. Fiellin Training HIV physicians to prescribe buprenorphine for opioid dependence Subst Abus 27 3 2006 13 18
37. C.B. Hurt, J.J. Eron Jr, M.S. Cohen Pre-exposure prophylaxis and antiretroviral resistance: HIV prevention at a cost? Clin Infect Dis 53 12 2011 1265 1270
38. W.C. Becker, D.G. Tobin, D.A. Fiellin Nonmedical use of opioid analgesics obtained directly from physicians: prevalence and correlates Arch Intern Med 171 11 2011 1034 1036
39. J.A. Inciardi, H.L. Surratt, S.P. Kurtz, T.J. Cicero Mechanisms of prescription drug diversion among drug-involved club- and street-based populations Pain Med 8 2 2007 171 183
40. G. Guest, D. Shattuck, L. Johnson Changes in sexual risk behavior among participants in a PrEP HIV prevention trial Sex Transm Dis 35 12 2008 1002 1008
41. A.J. Abraham, L.A. O'Brien, B.E. Bride, P.M. Roman HIV/AIDS services in private substance abuse treatment programs Drug Alcohol Depend 115 1-2 2011 16 22
42. L.S. Brown Jr, S. Kritz, R.J. Goldsmith Health services for HIV/AIDS, HCV, and sexually transmitted infections in substance abuse treatment programs Public Health Rep 122 4 2007 441 451
43. E.J. Edelman, A.T. Dinh, B.A. Moore, R.S. Schottenfeld, D.A. Fiellin, L.E. Sullivan Human immunodeficiency virus testing practices among buprenorphine-prescribing physicians J Addict Med 6 2 2012 159 165
44. B.M. Branson, H.H. Handsfield, M.A. Lampe Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings MMWR Recomm Rep 55 RR-14 2006 1 17 quiz CE1-4
45. DHHS and CDC. A guide to taking a sexual history. CDC publication 99-8445.
46. L.R. Metsch, D.J. Feaster, L. Gooden Implementing rapid HIV testing with or without risk-reduction counseling in drug treatment centers: results of a randomized trial Am J Public Health 102 6 2012 1160 1167
47. K. Underhill, D. Operario, M.J. Mimiaga, M.R. Skeer, K.H. Mayer Implementation science of pre-exposure prophylaxis: preparing for public use Curr HIV/AIDS Rep 7 4 2010 210 219
48. J.D. Baxter, R.E. Clark, M. Samnaliev, G.Y. Leung, L. Hashemi Factors associated with Medicaid patients' access to buprenorphine treatment J Subst Abuse Treat 41 1 2011 88 96
49. R.E. Clark, M. Samnaliev, J.D. Baxter, G.Y. Leung The evidence doesn't justify steps by state Medicaid programs to restrict opioid addiction treatment with buprenorphine Health Aff (Millwood) 30 8 2011 1425 1433
50. D.A. Fiellin The first three years of buprenorphine in the U.S.: experience to date and future directions J Addict Med 1 2 2007 62 67
51. R.C. Burke, K.A. Sepkowitz, K.T. Bernstein Why don't physicians test for HIV? A review of the U.S. literature AIDS 21 12 2007 1617 1624
52. A.A. Leibowitz, K.B. Parker, M.J. Rotheram-Borus A U.S. policy perspective on oral preexposure prophylaxis for HIV Am J Public Health 101 6 2011 982 985
53. D.P. Alford, C.T. LaBelle, N. Kretsch Collaborative care of opioid-addicted patients in primary care using buprenorphine: five-year experience Arch Intern Med 171 5 2011 425 431
54. D.A. Fiellin, M.V. Pantalon, M.C. Chawarski Counseling plus buprenorphine-naloxone maintenance therapy for opioid dependence N Engl J Med 355 4 2006 365 374
55. K.H. Wang, W.C. Becker, D.A. Fiellin Prevalence and correlates for nonmedical use of prescription opioids among urban and rural residents Drug Alcohol Depend 2012 Jul 20
56. S. Okie A flood of opioids, a rising tide of deaths N Engl J Med 363 21 2010 1981 1985
57. M. Ohl, J. Tate, M. Duggal Rural residence is associated with delayed care entry and increased mortality among veterans with human immunodeficiency virus infection Med Care 48 12 2010 1064 1070
58. B.J. Turner, C. Laine, Y.T. Lin, K. Lynch Barriers and facilitators to primary care or human immunodeficiency virus clinics providing methadone or buprenorphine for the management of opioid dependence Arch Intern Med 165 15 2005 1769 1776
59. A. Macher, E. Goosby, L. Barker Educating primary care providers about HIV disease: multidisciplinary interactive mechanisms Public Health Rep 109 3 1994 305 310
60. R.R. Waller, L.W. Lisella National AIDS hotline: HIV and AIDS information service through a toll-free telephone system Public Health Rep 106 6 1991 628 634
61. WESTAT and The AVISA Group. Evaluation of the Buprenorphine Waiver Program: buprenorphine reimbursement and availability tracking study, 2005. Report No.: Task Order 277-00-6111.
62. W. Kissin, C. McLeod, J. Sonnefeld, A. Stanton Experiences of a national sample of qualified addiction specialists who have and have not prescribed buprenorphine for opioid dependence J Addict Dis 25 4 2006 91 103
63. A. Stanton, C. McLeod, W. Kissin, J. Sonnefeld, J.W. Luckey Evaulation of the Buprenorphine Waiver Program: results from the SAMHSA/CSAT's evaluation of the Buprenorphine Waiver Program 2005 The College on Problems of Drug Dependence Orlando FL
64. C.O. Cunningham, A. Giovanniello, G. Sacajiu, X. Li, M. Brisbane, N.L. Sohler Inquiries about and initiation of buprenorphine treatment in an inner-city clinic Subst Abus 30 3 2009 261 262